8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 17, 2016

 

 

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-31141   33-0655706

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

784 Memorial Drive, Cambridge, MA   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 453-1000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

At our annual meeting of stockholders held on June 17, 2016, our stockholders voted on two matters as follows:

 

1. The following eight nominees were elected to our Board of Directors to serve for a one-year term expiring at the 2017 annual meeting of stockholders:

 

     Votes For      Votes
Against
     Votes
Abstaining
     Broker
Non-Votes
 

José Baselga, M.D., Ph.D.

     34,847,731         77,196         21,132         4,804,032   

Jeffrey Berkowitz, J.D.

     34,841,558         83,319         21,182         4,804,032   

Anthony B. Evnin, Ph.D.

     34,591,006         333,384         21,669         4,804,032   

Eric S. Lander, Ph.D.

     34,670,578         262,411         13,070         4,804,032   

Adelene Q. Perkins

     34,243,031         624,066         78,962         4,804,032   

Norman C. Selby

     34,801,506         123,195         21,358         4,804,032   

Ian F. Smith

     34,846,851         87,035         12,173         4,804,032   

Michael C. Venuti, Ph.D.

     34,832,820         100,958         12,281         4,804,032   

 

2. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the current fiscal year was ratified.

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

39,605,205   129,021   15,865  


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    INFINITY PHARMACEUTICALS, INC.
Date: June 22, 2016     By:   /s/ William C. Bertrand, Jr.
       

William C. Bertrand, Jr.

EVP, General Counsel